HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Federal Commitment To Reducing Animal Testing Called Into Question

This article was originally published in The Rose Sheet

Executive Summary

The animal protection community questions the "genuine commitment" of the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) in a June 7 response to the committee's draft five-year plan for reducing, refining and replacing the use of animals in toxicology testing

You may also be interested in...



PETA Becomes Revlon Shareholder, Seeking Visibility Into Animal Policies

People for the Ethical Treatment of Animals has purchased stock in Revlon, with the intent to issue a shareholder resolution calling for animal-testing transparency. The activist group says other cosmetics firms may be targeted in the future.

Major U.S. Cosmetic Firms Say They Are Ready For Animal Test Ban In EU

The EU's upcoming ban on products tested on animals could affect the availability of some novel cosmetic ingredients, though it is unlikely to have a jarring impact on large U.S. personal-care marketers

Major U.S. Cosmetic Firms Say They Are Ready For Animal Test Ban In EU

The EU's upcoming ban on products tested on animals could affect the availability of some novel cosmetic ingredients, though it is unlikely to have a jarring impact on large U.S. personal-care marketers

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel